Amgen (AMGN): financials, SEC filings and peers
Amgen (AMGN) is a biotechnology company in the Health Care sector of the S&P 500, headquartered in Thousand Oaks, California.
It was founded in 1980 and joined the S&P 500 on January 2, 1992.
Its fiscal year ends in December, and its shares trade on the Nasdaq.
In its SEC filings it is classified as “Biological Products, (No Diagnostic Substances)”.
Amgen at a glance
- Revenue (12 months)
- $38.1B
- Revenue growth
- +9.1%
- Operating margin
- 30.0%
- Net income (12 months)
- $8.7B
- Free cash flow (12 months)
- $10.2B
- Cash
- $14.0B
- Debt
- $57.3B
- Diluted EPS (12 months)
- $16.10
Twelve months to June 30, 2026, from the 10-Q filed August 5, 2026.
Latest twelve months
Over the twelve months to June 30, 2026, Amgen reported revenue of $38.1 billion, up 9.1% from a year earlier.
Its operating margin was 30.0%, up 6.5 percentage points from a year earlier: for every $100 of sales, about $30 was left as operating profit.
Net income was $8.7 billion (23.0% of revenue), 32.1% higher than a year earlier.
Operating cash flow was $12.5 billion and capital spending $2.3 billion, leaving free cash flow of $10.2 billion (26.7% of revenue).
At the end of the period it held $14.0 billion in cash and $57.3 billion in debt, a net debt position of $43.3 billion.
Five-year trend
- Revenue went from $25.4 billion in fiscal 2020 to $36.8 billion in fiscal 2025, about 7.6% a year.
- Revenue has grown for 5 fiscal years in a row.
- Operating margin narrowed from 35.9% to 24.7% over the same years.
- Free cash flow was positive in each of the last 6 fiscal years.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $26.0B | $26.3B | $28.2B | $33.4B | $36.8B |
| Revenue growth | 2.2% | 1.3% | 7.1% | 18.6% | 10.0% |
| Operating margin | 29.4% | 36.3% | 28.0% | 21.7% | 24.7% |
| Net income | $5.9B | $6.6B | $6.7B | $4.1B | $7.7B |
| Free cash flow | $8.4B | $8.8B | $7.4B | $10.4B | $8.1B |
| Diluted EPS | $10.28 | $12.11 | $12.49 | $7.56 | $14.23 |
Fiscal years as reported in Amgen’s 10-K filings. Free cash flow is operating cash flow minus capital spending.
Recent SEC filings
- 10-Q filed August 5, 2026 — quarterly report
- 8-K filed August 4, 2026 — Earnings results
- 8-K filed July 31, 2026
- 8-K filed May 20, 2026 — Shareholder vote results
- 8-K filed May 19, 2026 — Executive or director change
- 10-Q filed May 1, 2026 — quarterly report
- 8-K filed April 30, 2026 — Earnings results
- 8-K filed April 22, 2026 — Executive or director change
Companies like Amgen
Other S&P 500 companies in Biotechnology:
- ABBVAbbVieNorth Chicago, Illinois
- BIIBBiogenCambridge, Massachusetts
- GILDGilead SciencesFoster City, California
- INCYIncyteWilmington, Delaware
- MRNAModernaCambridge, Massachusetts
- REGNRegeneron PharmaceuticalsTarrytown, New York
- VRTXVertex PharmaceuticalsBoston, Massachusetts
More from Health Care
Questions about Amgen
Is Amgen's revenue growing?
Yes. Revenue for the twelve months to June 30, 2026 was $38.1 billion, up 9.1% from a year earlier, according to its SEC filings.
Is Amgen profitable?
Yes. It earned $8.7 billion in net income over the twelve months to June 30, 2026, a net margin of 23.0%.
Does Amgen have more cash or more debt?
At June 30, 2026 it had $14.0 billion in cash and $57.3 billion in debt, so more debt than cash.
When did Amgen last file financial results?
Its latest quarterly report (10-Q) was filed with the SEC on August 5, 2026.
Which companies are similar to Amgen?
In the S&P 500, Amgen is grouped in Biotechnology within the Health Care sector. AbbVie (ABBV), Biogen (BIIB), Gilead Sciences (GILD), Incyte (INCY), Moderna (MRNA) are in the same group.
Understand the numbers
Source: Amgen’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved September 27, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.